A myristoyl/phosphotyrosine switch regulates c-Abl

Cell

Volumn 112, Issue 6, 2003, Pages 845-857

  Hantschel, Oliver ^a   Nagar, Bhushan ^c   Guettler, Sebastian ^a   Kretzschmar, Jana ^a   Dorey, Karel ^a,e   Kuriyan, John ^c,d   Superti Furga, Giulio ^a,b  

^a EUROPEAN MOLECULAR BIOLOGY LABORATORY   (Germany)

^b GLAXOSMITHKLINE   (United Kingdom)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d LAWRENCE BERKELEY NATIONAL LABORATORY   (United States)

^e IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; ONCOPROTEIN; PHOSPHOTYROSINE; PROTEIN TYROSINE KINASE;

ARTICLE; CELL ACTIVATION; DRUG MECHANISM; DRUG SENSITIVITY; ENZYME REGULATION; MOLECULAR INTERACTION; MYRISTYLATION; ONCOGENE; PRIORITY JOURNAL; REGULATORY MECHANISM; STRUCTURE ANALYSIS;

EID: 0344626925     PISSN: 00928674     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0092-8674(03)00191-0     Document Type: Article

References (63)

1. Azam M., Latek R.R., Daley G.Q. Mechanisms of autoinhibition and STI-157/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell. 112:2003;831-843. this issue,
2. Barilá D., Superti-Furga G. An intramolecular SH3-domain interaction regulates c-Abl activity. Nat. Genet. 18:1998;280-282.
3. Barilá D., Mangano R., Gonfloni S., Kretzschmar J., Moro M., Bohmann D., Superti-Furga G. A nuclear tyrosine phosphorylation circuit. c-Jun as an activator and substrate of c-Abl and JNK EMBO J. 19:2000;273-281.
4. Blume-Jensen P., Hunter T. Oncogenic kinase signaling. Nature. 411:2001;355-365.
5. Brasher B.B., Van Etten R.A. c-Abl has high intrinsic tyrosine kinase activity that is stimulated by mutation of the src homology 3 domain and by autophosphorylation at two distinct regulatory tyrosines. J. Biol. Chem. 275:2000;35631-35637.
6. Brasher B.B., Roumiantsev S., Van Etten R.A. Mutational analysis of the regulatory function of the c-Abl Src homology 3 domain. Oncogene. 20:2001;7744-7752.
7. Cong F., Spencer S., Cote J.F., Wu Y., Tremblay M.L., Lasky L.A., Goff S.P. Cytoskeletal protein PSTPIP1 directs the PEST-type protein tyrosine phosphatase to the c-Abl kinase to mediate Abl dephosphorylation. Mol. Cell. 6:2000;1413-1423.
8. Cox S., Radzio-Andzelm E., Taylor S.S. Domain movements in protein kinases. Curr. Opin. Struct. Biol. 4:1994;893-901.
9. Daley G.Q., Van Etten R.A., Jackson P.K., Bernards A., Baltimore D. Nonmyristoylated Abl proteins transform a factor-dependent hematopoietic cell line. Mol. Cell. Biol. 12:1992;1864-1871.
10. Dorey K., Engen J.R., Kretzschmar J., Wilm M., Neubauer G., Schindler T., Superti-Furga G. Phosphorylation and structure-based functional studies reveal a positive and a negative role for the activation loop of the c-Abl tyrosine kinase. Oncogene. 20:2001;8075-8084.
11. Druker B.J., Tamura S., Buchdunger E., Ohno S., Segal G.M., Fanning S., Zimmermann J., Lydon N.B. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med. 2:1996;561-566.
12. Feller S.M., Ren R., Hanafusa H., Baltimore D. SH2 and SH3 domains as molecular adhesives. the interactions of Crk and Abl Trends Biochem. Sci. 19:1994;453-458.
13. Furstoss O., Dorey K., Simon V., Barila D., Superti-Furga G., Roche S. c-Abl is an effector of Src for growth factor-induced c-myc expression and DNA synthesis. EMBO J. 21:2002;514-524.
14. Gonfloni S., Williams J.C., Hattula K., Weijland A., Wierenga R.K., Superti-Furga G. The role of the linker between the SH2 domain and catalytic domain in the regulation and function of Src. EMBO J. 16:1997;7261-7271.
15. Gonfloni S., Frischknecht F., Way M., Superti-Furga G. Leucine 255 of Src couples intramolecular interactions to inhibition of catalysis. Nat. Struct. Biol. 6:1999;760-764.
16. Gonfloni S., Weijland A., Kretzschmar J., Superti-Furga G. Crosstalk between the catalytic and regulatory domains allows bidirectional regulation of Src. Nat. Struct. Biol. 7:2000;281-286.
17. Hardin J.D., Boast S., Mendelsohn M., de los Santos K., Goff S.P. Transgenes encoding both type I and type IV c-abl proteins rescue the lethality of c-abl mutant mice. Oncogene. 12:1996;2669-2677.
18. Hubbard S.R. Structural analysis of receptor tyrosine kinases. Prog. Biophys. Mol. Biol. 71:1999;343-358.
19. Hubbard S.R. Protein tyrosine kinases. autoregulation and small-molecule inhibition Curr. Opin. Struct. Biol. 12:2002;735-741.
20. Hubbard S.R., Till J.H. Protein tyrosine kinase structure and function. Annu. Rev. Biochem. 69:2000;373-398.
21. Huse M., Kuriyan J. The conformational plasticity of protein kinases. Cell. 109:2002;275-282.
22. Jackson P., Baltimore D. N-terminal mutations activate the leukemogenic potential of the myristoylated form of c-abl. EMBO J. 8:1989;449-456.
23. Koleske A.J., Gifford A.M., Scott M.L., Nee M., Bronson R.T., Miczek K.A., Baltimore D. Essential roles for the Abl and Arg tyrosine kinases in neurulation. Neuron. 21:1998;1259-1272.
24. Liu X., Brodeur S.R., Gish G., Songyang Z., Cantley L.C., Laudano A.P., Pawson T. Regulation of c-Src tyrosine kinase activity by the Src SH2 domain. Oncogene. 8:1993;1119-1126.
25. Manning G., Whyte D.B., Martinez R., Hunter T., Sudarsanam S. The protein kinase complement of the human genome. Science. 298:2002;1912-1934.
26. Mayer B.J., Jackson P.K., Van Etten R.A., Baltimore D. Point mutations in the abl SH2 domain coordinately impair phosphotyrosine binding in vitro and transforming activity in vivo. Mol. Cell. Biol. 12:1992;609-618.
27. McWhirter J.R., Galasso D.L., Wang J.Y. A coiled-coil oligomerization domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins. Mol. Cell. Biol. 13:1993;7587-7595.
28. Moarefi I., LaFevre-Bernt M., Sicheri F., Huse M., Lee C.H., Kuriyan J., Miller W.T. Activation of the Src-family tyrosine kinase Hck by SH3 domain displacement. Nature. 385:1997;650-653.
29. Musacchio A., Saraste M., Wilmanns M. High-resolution crystal structures of tyrosine kinase SH3 domains complexed with proline-rich peptides. Nat. Struct. Biol. 1:1994;546-551.
30. Nagar B., Bornmann W.G., Pellicena P., Schindler T., Veach D.R., Miller W.T., Clarkson B., Kuriyan J. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res. 62:2002;4236-4243.
31. Nagar B., Hantschel O., Young M.A., Scheffzek K., Veach D., Bornmann W., Clarkson B., Superti-Furga G., Kuriyan J. Structural basis for the autoinhibition of c-Abl tyrosine kinase. Cell. 112:2003;859-871. this issue,
32. Pendergast A.M. The Abl family kinases. mechanisms of regulation and signaling Adv. Cancer Res. 85:2002;51-100.
33. Plattner R., Kadlec L., DeMali K.A., Kazlauskas A., Pendergast A.M. c-Abl is activated by growth factors and src family kinases and has a role in the cellular response to PDGF. Genes Dev. 13:1999;2400-2411.
34. Pluk H., Dorey K., Superti-Furga G. Autoinhibition of c-Abl. Cell. 108:2002;247-259.
35. Porter M., Schindler T., Kuriyan J., Miller W.T. Reciprocal regulation of Hck activity by phosphorylation of Tyr(527) and Tyr(416). Effect of introducing a high affinity intramolecular SH2 ligand. J. Biol. Chem. 275:2000;2721-2726.
36. Raitano A.B., Whang Y.E., Sawyers C.L. Signal transduction by wild-type and leukemogenic Abl proteins. Biochim. Biophys. Acta. 1333:1997;F201-F216.
37. Renshaw M.W., Capozza M.A., Wang J.Y. Differential expression of type-specific c-abl mRNAs in mouse tissues and cell lines. Mol. Cell. Biol. 8:1988;4547-4551.
38. Resh M.D. Myristylation and palmitylation of Src family members. the fats of the matter Cell. 76:1994;411-413.
39. Resh M.D. Fatty acylation of proteins. new insights into membrane targeting of myristoylated and palmitoylated proteins Biochim. Biophys. Acta. 1451:1999;1-16.
40. Roumiantsev S., Shah N.P., Gorre M.E., Nicoll J., Brasher B.B., Sawyers C.L., Van Etten R.A. Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop. Proc. Natl. Acad. Sci. USA. 99:2002;10700-10705.
41. Roussel R.R., Brodeur S.R., Shalloway D., Laudano A.P. Selective binding of activated pp60c-src by an immobilized synthetic phosphopeptide modeled on the carboxyl terminus of pp60c-src. Proc. Natl. Acad. Sci. USA. 88:1991;10696-10700.
42. Sawyers C.L. Disabling Abl-perspectives on Abl kinase regulation and cancer therapeutics. Cancer Cell. 1:2002;13-15.
43. Schindler T., Bornmann W., Pellicena P., Miller W.T., Clarkson B., Kuriyan J. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science. 289:2000;1938-1942.
44. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell. 103:2000;211-225.
45. Schwartzberg P.L., Stall A.M., Hardin J.D., Bowdish K.S., Humaran T., Boast S., Harbison M.L., Robertson E.J., Goff S.P. Mice homozygous for the ablm1 mutation show poor viability and depletion of selected B and T cell populations. Cell. 65:1991;1165-1175.
46. Sicheri F., Moarefi I., Kuriyan J. Crystal structure of the Src family tyrosine kinase Hck. Nature. 385:1997;602-609.
47. Smith J.M., Mayer B.J. Abl. mechanisms of regulation and activation Front. Biosci. 7:2002;d31-d42.
48. Superti-Furga G., Courtneidge S.A. Structure-function relationships in Src family and related protein tyrosine kinases. Bioessays. 17:1995;321-330.
49. Taagepera S., McDonald D., Loeb J.E., Whitaker L.L., McElroy A.K., Wang J.Y., Hope T.J. Nuclear-cytoplasmic shuttling of C-ABL tyrosine kinase. Proc. Natl. Acad. Sci. USA. 95:1998;7457-7462.
50. Taniguchi H. Protein myristoylation in protein-lipid and protein-protein interactions. Biophys. Chem. 82:1999;129-137.
51. Taylor S.S., Radzio-Andzelm E. Protein kinase inhibition. natural and synthetic variations on a theme Curr. Opin. Chem. Biol. 1:1997;219-226.
52. Tybulewicz V.L.J., Crawford C.E., Jackson P.K., Bronson R.T., Mulligan R.C. Neonatal lethality and lymphopenia in mice with a homozygous disruption of the c-abl proto-oncogene. Cell. 65:1991;1153-1163.
53. Van Etten R.A. Cycling, stressed-out and nervous. cellular functions of c-Abl Trends Cell Biol. 9:1999;179-186.
54. Van Etten R.A., Jackson P.K., Baltimore D., Sanders M.C., Matsudaira P.T., Janmey P.A. The COOH terminus of the c-Abl tyrosine kinase contains distinct F- and G-actin binding domains with bundling activity. J. Cell Biol. 124:1994;325-340.
55. Williams J.C., Weijland A., Gonfloni S., Thompson A., Courtneidge S.A., Superti-Furga G., Wierenga R.K. The 2.35 Å crystal structure of the inactivated form of chicken Src. a dynamic molecule with multiple regulatory interactions J. Mol. Biol. 274:1997;757-775.
56. Woodring P.J., Litwack E.D., O'Leary D.D., Lucero G.R., Wang J.Y., Hunter T. Modulation of the F-actin cytoskeleton by c-Abl tyrosine kinase in cell spreading and neurite extension. J. Cell Biol. 156:2002;879-892.
57. Xu W., Harrison S.C., Eck M.J. Three-dimensional structure of the tyrosine kinase c-Src. Nature. 385:1997;595-601.
58. Yano H., Cong F., Birge R.B., Goff S.P., Chao M.V. Association of the Abl tyrosine kinase with the Trk nerve growth factor receptor. J. Neurosci. Res. 59:2000;356-364.
59. Young M.A., Gonfloni S., Superti-Furga G., Roux B., Kuriyan J. Dynamic coupling between the SH2 and SH3 domains of c-Src and Hck underlies their inactivation by C-terminal tyrosine phosphorylation. Cell. 105:2001;115-126.
60. Yu H.H., Zisch A.H., Dodelet V.C., Pasquale E.B. Multiple signaling interactions of Abl and Arg kinases with the EphB2 receptor. Oncogene. 20:2001;3995-4006.
61. rd, Eck M.J., Harrison S.C., Feldman R.A., Mohammadi M., Schlessinger J., Hubbard S.R., Smith D.P., Eng C.et al. Catalytic specificity of protein-tyrosine kinases is critical for selective signalling. Nature. 373:1995;536-539.
62. Zhu G., Decker S.J., Maclean D., McNamara D.J., Singh J., Sawyer T.K., Saltiel A.R. Sequence specificity in the recognition of the epidermal growth factor receptor by the abl Src homology 2 domain. Oncogene. 9:1994;1379-1385.
63. Zipfel P.A., Grove M., Blackburn K., Fujimoto M., Tedder T.F., Pendergast A.M. The c-Abl tyrosine kinase is regulated downstream of the B cell antigen receptor and interacts with CD19. J. Immunol. 165:2000;6872-6879.